Clinical trials: LOCALLY ADVANCED RECTAL CANCER
Locally Advanced Rectal Cancer, Rectal Adenocarcinoma
Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer
This prospective national multicentre feasibility study evaluates dose-escalated short-course proton radiotherapy followed by total neoadjuvant chemotherapy in patients with primary high-risk locally advanced rectal…
- Trial name
- PROSPECT-WW (NCT07903883)
- Testing
- Intensity modulated proton therapy
- Where
- 8 sites in Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Rectal Cancer, Colo-rectal Cancer
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
The objectives of this study are to: 1. To assess dose-limiting toxicities (DLTs) of capecitabine +/- oxaliplatin in a combination regimen with capecitabine and radiotherapy (Phase 1) 2.
- Trial name
- NCT00226941
- Testing
- Cetuximab, Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- George Albert Fisher
Locally Advanced Rectal Carcinoma, Circulating Tumor DNA
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
Rectal cancer still remains one of the most popular tumors, however, distance metastasis still remains as high as 30% and the long-term survival outcomes are still unsatisfying.
- Trial name
- CINTS-R (NCT05601505)
- Testing
- circulating tumor DNA
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Peking Union Medical College Hospital
Rectal Cancer
Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy
feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma collection of response rate (T- and…
- Trial name
- NCT00671645
- Testing
- capecitabine, bevacizumab
- Where
- 10 sites in Austria
- Volunteers
- 8 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial aims to assessing the efficacy and safety of neoadjuvant chemoradiation plus Tislelizumab (PD-1 inhibitor) with or without Probio-M9 and subsequent TME surgery, by…
- Conditions
- Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
- Trial name
- NCRIT-PM9 (NCT07458529)
- Testing
- CRT+PD-1 inhibitor+Probio-M9
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Seventh Medical Center of PLA General Hospital
Rectal Cancer, Locally Advanced Rectal Cancer
A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue
This clinical study investigates the anti-inflammatory and anti-cancer properties of a high-bioavailability formulation of curcumin (BCM-95) in patients with mid-to-low rectal cancer receiving neoadjuvant chemoradiotherapy…
- Conditions
- Rectal Cancer, Locally Advanced Rectal Cancer, Radiation-Induced Enteritis, Radiation Proctitis
- Trial name
- BCMRECRAD (NCT07248020)
- Testing
- Curcumin (BCM-95®)
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- Chang Gung Memorial Hospital
Rectal Cancer
Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer
The goal of this clinical trial is to learn if node-sparing modified short-course radiotherapy combined with tislelizumab and CAPOX works to treat pMMR/MSS locally advanced mid-to-low rectal cancer.
- Trial name
- mRCATS (NCT07900061)
- Testing
- node-sparing modified short-course radiotherapy, standard short-course radiotherapy
- Volunteers
- 210 people
- Sponsor
- Sir Run Run Shaw Hospital
Locally Advanced Rectal Carcinoma
Preoperative, Adaptive Radiotherapy Concomitant to Chemotherapy for Rectal Adenocarcinoma (Adaptive Rectal Cancer Trial 02)
The aim of this clinical study is to increase the rate of pathological responses up to 70% by means of improved patient selection operated by a radiobiological index called ERI_TCP and by an increase in the dose of radiotherapy…
- Trial name
- NCT07580027
- Testing
- Preoperative, adaptive radiotherapy
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- IRCCS San Raffaele
Locally Advanced Rectal Cancer
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
The main purpose of the study was to define maximum tolerated dose (MTD), recommended Phase II dose (RP2D) safety and tolerability of Peposertib in combination with capecitabine and radiotherapy (RT).
- Trial name
- NCT03770689
- Testing
- Peposertib 50 mg, Peposertib 100 mg, Peposertib 150 mg
- Where
- 14 sites in United States, Spain
- Volunteers
- 19 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Neoplasms, Rectal
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
The purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior…
- Trial name
- AZUR-1 (NCT05723562)
- Testing
- Dostarlimab
- Where
- 42 sites in United States, Canada and 8 more
- Volunteers
- 154 people
- Sponsor
- GlaxoSmithKline
Rectum Cancer
Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients
A phase II clinical trial compared standard TNT (mFolfox6 and CRT) with preoperative chemoradiotherapy (CRT) with neoadjuvant chemotherapy (CT) containing mFolfirinox in patients with locally advanced rectal cancer.
- Trial name
- NCT06812728
- Testing
- mFOLFIRINOX, mFolfox6
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Menoufia University
Rectal Adenocarcinoma
Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum
This is a retrospective study comparing neoadjuvent short course radiotherapy to conventional chemoradiation in locally advanced cancer rectum and the effect of both regimens in overall survival and disease free survival
- Trial name
- NCT04814784
- Testing
- Neoadjuvent radiotherapy either short or long course chemoradiation in treatment of locally advanced cancer rectum
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Amany sayed Abass
Rectal Cancer
A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer
This is an open-label, randomized phase II study. Patients will be randomly assigned to either FL or TS-1/irinotecan preoperative chemotherapy regimens by stratification.
- Trial name
- NCT01269216
- Testing
- 5-FU with leucovorin, TS-1 with Irinotecan
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Yonsei University
Rectal Cancer
Preoperative Panitumumab and Radiotherapy in Rectal Cancer
The purpose of this study is to investigate the activity of panitumumab in combination with standard preoperative radiotherapy in locally advanced rectal cancer, followed by complete surgery and adjuvant chemotherapy.
- Trial name
- PrePaRad (NCT00973193)
- Testing
- panitumumab
- Where
- 8 sites in Belgium
- Volunteers
- 20 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Colorectal Cancer
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery.
- Trial name
- NCT01515787
- Testing
- FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery
- Where
- 1,073 sites in United States, Canada and 2 more
- Volunteers
- 1,194 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Advanced Rectal Cancer, Abdominoperineal Resection
Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters
The intention of the study is to explore metabolic and inflammatory parameters in the pelvis after abdominoperineal resection for locally advanced rectal cancer in patients that have received radiation therapy before surgery.
- Conditions
- Locally Advanced Rectal Cancer, Abdominoperineal Resection, Infection
- Trial name
- NCT03392584
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- Oslo University Hospital
Rectal Cancer, Locally Advanced Rectal Carcinoma
MRI T1 Relaxation Time in Rectal Cancer
The goal of this observational study is to learn about the T1 relaxation time and T1 relaxation time properties of the disease in people with locally advanced rectal cancer.
- Trial name
- NCT05876026
- Where
- Denmark
- Volunteers
- 44 people
- Sponsor
- Vejle Hospital
Rectal Cancer, Advanced Cancer
Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer
This study is a non-inferiority phase III randomised trial comparing preoperative chemotherapy alone (modified FOLFIRINOX) to chemotherapy followed by chemoradiotherapy in patients with primary resectable locally advanced rectal…
- Trial name
- NORAD01 (NCT03875781)
- Testing
- Chemotherapy, Radiochemotherapy
- Where
- France
- Volunteers
- 540 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rectal Cancer, Rectal Adenocarcinoma
Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma
This research study is designed to see if Capecitabine and Lenvatinib in combination with external radiation therapy are effective in treating locally advanced rectal adenocarcinoma in patients who have not yet had surgery, and…
- Trial name
- NCT02935309
- Testing
- Lenvatinib, Capecitabine, External Radiation Therapy (XRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
This randomized phase II trial studies how well cisplatin and fluorouracil work compared with carboplatin and paclitaxel in treating patients with anal cancer that cannot be removed by surgery, has come back at or near the same…
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma
- Trial name
- InterAACT (NCT02560298)
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- ECOG-ACRIN Cancer Research Group